Immunoglobulin News and Research

RSS

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Memory B cells persist in recovered COVID-19 patients

A team of scientists from the University of Washington, USA, and the Karolinska Institute, Sweden, has comprehensively studied the antibody-mediated immune responses in patients diagnosed with coronavirus disease 2019 (COVID-19).

30 Nov 2020

Researchers highlight potential advantages of mucosal vaccine

Anyone who has undergone a nasal swab or saliva test for COVID-19 knows that the virus is most easily detected in the nose and mouth.

30 Nov 2020

COVID-19 studies have neglected to focus on mucosal immunity, researchers argue

Researchers suggest that COVID-19 studies should focus on how mucous membranes in the mouth and nose develop immunity to the SARS-CoV-2 virus.

27 Nov 2020

SARS-CoV-2 immunity can sustain for at least eight months, study finds

A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.

26 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

In the face of discouraging news about the resurgence of COVID-19, some reports offer hope of protection in the face of a robust and persistent immune response. In an encouraging report, an Austrian preprint appearing on the medRxiv server in November 2020 suggests a high level of durable immunity to SARS-CoV-2 over at least six months.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

In a recent study published in the preprint server bioRxiv, researchers from the Grifols Bioscience Research Group reported on the collection of convalescent plasma and production of anti-SARS-CoV-2 hyperimmune globulin for use in clinical research.

22 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

Study: e-cigarette users have increased susceptibility to flu, COVID-19

In a controlled study of smokers, nonsmokers, and e-cigarette users, University of North Carolina School of Medicine researchers found that e-cigarette users exhibited significantly altered immune responses to a model of influenza virus infection, suggesting increased susceptibility to disease.

18 Nov 2020

SARS-CoV-2 was circulating in Italy before China recognized its existence

This study, published in the Tumori Journal, sheds light on the possibility that the virus had been spreading in Italy well before the outbreak was officially reported in Wuhan, China.

17 Nov 2020

Nanobodies: unharnessed potential in COVID-19 treatment

A new study published in the Journal of Biomolecular Structure and Dynamics in October 2020 discusses the use of nanobodies in diagnosing and treating this deadly disease.

16 Nov 2020

New saliva-based test found to accurately detect the presence of SARS-CoV-2 antibodies

A new saliva-based test developed by a team at Johns Hopkins Bloomberg School of Public Health has been found to accurately detect the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19, from small samples of saliva, according to a study led by Bloomberg School researchers.

15 Nov 2020

High prevalence of cross-reactive anti-SARS-CoV-2 antibodies in sub-Saharan Africa

A recent study published in the International Journal of Infectious Diseases has explained the lower prevalence of coronavirus disease 2019 (COVID-19) in sub-Saharan Africa compared to that in the US, Europe, and Asia.

15 Nov 2020

Beckman Coulter introduces new SARS-CoV-2 IgM assay in countries accepting the CE Mark

Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M assay in countries accepting the CE Mark.

From Beckman Coulter Diagnostics 12 Nov 2020

Research shows a unique T cell receptor repertoire in MIS-C patients

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv in November 2020, as a response to superantigen activation.

11 Nov 2020

Low prevalence of SARS-CoV-2 specific antibodies in Lubbock, Texas

A recent study published in the Journal of Primary Care and Community Health has assessed the prevalence of antibodies developed specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in front-line workers in Lubbock, Texas. According to the study findings, immunoglobulin G (IgG)-specific anti-SARS-CoV-2 antibodies have been detected in only 0.73% of the participants.

11 Nov 2020

Babies can acquire allergies from their mothers in the womb

Mothers can pass on allergies to offspring while they are developing in the womb and that is one reason why babies exhibit allergies early in life, according to a Singapore preclinical study.

10 Nov 2020